rabbit anti cd9 Search Results


94
Bioss cd9 polyclonal antibody
Cd9 Polyclonal Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+cd9/custom%40bs-23035r%4040023928?v=Bioss
Average 94 stars, based on 1 article reviews
cd9 polyclonal antibody - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

N/A
Rabbit Anti CD9 Polyclonal Antigen affinity Purified (PBS with 0.05% NaN3 and 40% Glycerol, pH7.4) (IHC,ELISA) from Innovative Research is a polyclonal antibody in a liquid format, buffered in PBS with 0.05% NaN3 and 40%
  Buy from Supplier

94
Boster Bio rabbit polyclonal anti cd9
Rabbit Polyclonal Anti Cd9, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+cd9/10__1134_slash_s1990747825700576-68-24-52?v=Boster+Bio
Average 94 stars, based on 1 article reviews
rabbit polyclonal anti cd9 - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

90
ZenBio rabbit anti-mouse cd9
Procedures and characteristics of SEC for separating EVs from serum. ( A ) Schematic overview of the experimental workflow. ( B ) Concentrations of particles and proteins in the SEC fractions were determined with nanoparticle tracking analysis (gray) and BCA (red), respectively. Data shows all 24 fractions. ( C ) SDS-PAGE was used to determine to directly visualize the relative presence of proteins in the all collected fractions, 15 μL of each fraction was mixed with 5 μL 4-fold concentrated reducing sample buffer, boiled for 5 minutes, and loaded on a 10% gradient gel. ( D ) The presence of the vesicle marker <t>CD9,</t> CD81, and the serum contaminant protein albumin and apolipoprotein marker apoA were determined in pooled EVs concentrates of fractions 8–13 and pooled Non-EVs concentrates fractions 14–24 with Western blot. ( E ) Droplets of fractions 9–11 and 20 were loaded onto grids, negative stained, and evaluated with transmission electron microscopy (TEM). Examples of EV-like structures (cup-shaped) are indicated by white arrows. Scale bars are 200 nm.
Rabbit Anti Mouse Cd9, supplied by ZenBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+cd9/pmc08487857-93-4-8?v=ZenBio
Average 90 stars, based on 1 article reviews
rabbit anti-mouse cd9 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

N/A
Rabbit Anti-Human CD9 (Center) Antibody, 400 µl
  Buy from Supplier

N/A
Rabbit Anti CD9 Polyclonal Affinity Purified (PBS with 0.02% sodium azide, 50% glycerol, pH7.3) (Western Blot) from Innovative Research is a polyclonal antibody in a liquid format, buffered in PBS with 0.02% sodium azide, 50%
  Buy from Supplier

N/A
Rabbit anti-Human CD9 Polyclonal Antibody
  Buy from Supplier

N/A
Rabbit anti-Human CD9 Polyclonal Antibody
  Buy from Supplier

N/A
Rabbit Anti Human CD9 Monoclonal Clone CED-3 from Innovative Research is a monoclonal antibody in a Liquid format, buffered in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol, 0.4-0.5mg/ml BSA.
  Buy from Supplier

N/A
CD9 Polyclonal Antibody
  Buy from Supplier

Image Search Results


Procedures and characteristics of SEC for separating EVs from serum. ( A ) Schematic overview of the experimental workflow. ( B ) Concentrations of particles and proteins in the SEC fractions were determined with nanoparticle tracking analysis (gray) and BCA (red), respectively. Data shows all 24 fractions. ( C ) SDS-PAGE was used to determine to directly visualize the relative presence of proteins in the all collected fractions, 15 μL of each fraction was mixed with 5 μL 4-fold concentrated reducing sample buffer, boiled for 5 minutes, and loaded on a 10% gradient gel. ( D ) The presence of the vesicle marker CD9, CD81, and the serum contaminant protein albumin and apolipoprotein marker apoA were determined in pooled EVs concentrates of fractions 8–13 and pooled Non-EVs concentrates fractions 14–24 with Western blot. ( E ) Droplets of fractions 9–11 and 20 were loaded onto grids, negative stained, and evaluated with transmission electron microscopy (TEM). Examples of EV-like structures (cup-shaped) are indicated by white arrows. Scale bars are 200 nm.

Journal: International Journal of Nanomedicine

Article Title: An Isolation System to Collect High Quality and Purity Extracellular Vesicles from Serum

doi: 10.2147/IJN.S328325

Figure Lengend Snippet: Procedures and characteristics of SEC for separating EVs from serum. ( A ) Schematic overview of the experimental workflow. ( B ) Concentrations of particles and proteins in the SEC fractions were determined with nanoparticle tracking analysis (gray) and BCA (red), respectively. Data shows all 24 fractions. ( C ) SDS-PAGE was used to determine to directly visualize the relative presence of proteins in the all collected fractions, 15 μL of each fraction was mixed with 5 μL 4-fold concentrated reducing sample buffer, boiled for 5 minutes, and loaded on a 10% gradient gel. ( D ) The presence of the vesicle marker CD9, CD81, and the serum contaminant protein albumin and apolipoprotein marker apoA were determined in pooled EVs concentrates of fractions 8–13 and pooled Non-EVs concentrates fractions 14–24 with Western blot. ( E ) Droplets of fractions 9–11 and 20 were loaded onto grids, negative stained, and evaluated with transmission electron microscopy (TEM). Examples of EV-like structures (cup-shaped) are indicated by white arrows. Scale bars are 200 nm.

Article Snippet: CD9 was detected using rabbit anti-mouse CD9 (220642, Zen Bio, 1:1000); CD63 with rabbit anti-mouse CD63 (510953, Zen Bio, 1:1000); CD81 with rabbit anti-mouse CD81 (381296, Zen Bio, 1:1000); apoA1 with rabbit anti-mouse apoA1 (381145, Zen Bio, 1:1000); Albumin with rabbit anti-mouse Albumin (ab207327, Abcam, 1:1000).

Techniques: SDS Page, Marker, Western Blot, Staining, Transmission Assay, Electron Microscopy

Systematically compare the separation efficiency of SEC, UC, and TEI. ( A ) Schematic overview of the experimental workflow. ( B ) total protein was determined by BCA (expressed as mg/mL originating serum; mean ± SD, n = 3). ( C ) the concentration of particles as detected by NTA (particles/mL originating serum; mean ± SD, n = 3). ( D ) the ratio of particle to protein for SEC, UC, and TEI. ( E ) size distribution of particles detected in C (representative for n = 3). The particle size at peak optimum is indicated. ( F ) samples were analyzed by SDS-PAGE followed by Bio-Safe Coomassie G-250. ( G ) the same samples were analyzed by Western blotting for the presence of the EV markers CD9, CD81, CD63, and the serum contaminant protein albumin and apolipoprotein marker apoA. The experiment shown is representative of 3 independent experiments. ( F and G ) SEC, TEI, and UC samples are all separated from equivalent volumes of 1mL originating serum, and the final volume is 100 μL. UCx3 samples were separated from 3mL originating serum, and the final volume is 100 μL. All samples were loaded on equal volumes for electrophoresis. ( H ) The whole amount of TEM images of particles collected by SEC, UC, or TEI. Examples of EV-like structures (cup-shaped) are indicated by white arrows. Scale bars are 500 nm. Data were used for comparative analysis and presented as columns with bars representing means ± SD. Marks: *p≤0.05; **p≤0.01; ***p≤0.001 and non-significant differences were indicated using ns symbol.

Journal: International Journal of Nanomedicine

Article Title: An Isolation System to Collect High Quality and Purity Extracellular Vesicles from Serum

doi: 10.2147/IJN.S328325

Figure Lengend Snippet: Systematically compare the separation efficiency of SEC, UC, and TEI. ( A ) Schematic overview of the experimental workflow. ( B ) total protein was determined by BCA (expressed as mg/mL originating serum; mean ± SD, n = 3). ( C ) the concentration of particles as detected by NTA (particles/mL originating serum; mean ± SD, n = 3). ( D ) the ratio of particle to protein for SEC, UC, and TEI. ( E ) size distribution of particles detected in C (representative for n = 3). The particle size at peak optimum is indicated. ( F ) samples were analyzed by SDS-PAGE followed by Bio-Safe Coomassie G-250. ( G ) the same samples were analyzed by Western blotting for the presence of the EV markers CD9, CD81, CD63, and the serum contaminant protein albumin and apolipoprotein marker apoA. The experiment shown is representative of 3 independent experiments. ( F and G ) SEC, TEI, and UC samples are all separated from equivalent volumes of 1mL originating serum, and the final volume is 100 μL. UCx3 samples were separated from 3mL originating serum, and the final volume is 100 μL. All samples were loaded on equal volumes for electrophoresis. ( H ) The whole amount of TEM images of particles collected by SEC, UC, or TEI. Examples of EV-like structures (cup-shaped) are indicated by white arrows. Scale bars are 500 nm. Data were used for comparative analysis and presented as columns with bars representing means ± SD. Marks: *p≤0.05; **p≤0.01; ***p≤0.001 and non-significant differences were indicated using ns symbol.

Article Snippet: CD9 was detected using rabbit anti-mouse CD9 (220642, Zen Bio, 1:1000); CD63 with rabbit anti-mouse CD63 (510953, Zen Bio, 1:1000); CD81 with rabbit anti-mouse CD81 (381296, Zen Bio, 1:1000); apoA1 with rabbit anti-mouse apoA1 (381145, Zen Bio, 1:1000); Albumin with rabbit anti-mouse Albumin (ab207327, Abcam, 1:1000).

Techniques: Concentration Assay, SDS Page, Western Blot, Marker, Electrophoresis

Comparison of two different combination methods and SEC. ( A ) Schematic overview of the experimental workflow. ( B ) total protein was determined by BCA (expressed as mg/mL originating serum; mean ± SD, n = 3). ( C ) the concentration of particles as detected by NTA (particles/mL originating serum; mean ± SD, n = 3). ( D ) the ratio of particle to protein for SEC, SEC+UC, and SEC+TEI. ( E ) size distribution of particles detected in C (representative for n = 3). The particle size at peak optimum is indicated. ( F ) samples were analyzed by SDS-PAGE followed by Bio-Safe Coomassie G-250. ( G ) the same samples were analyzed by Western blotting for the presence of the EV markers CD9, CD81, CD63, and the serum contaminant protein albumin and apolipoprotein marker apoA. The experiment shown is representative of 3 independent experiments. ( F and G ) SEC, SEC+UC, and SEC+TEI samples are all separated from equivalent volumes of 1mL originating serum, and the final volume is 100 μL. SEC+UCx3 samples were separated from 3mL originating serum, and the final volume is 100μL. All samples were loaded on equal volumes for electrophoresis. ( H ) The whole amount of TEM images of particles collected by SEC, SEC+UC, or SEC+TEI. Examples of EV-like structures (cup-shaped) are indicated by white arrows. Scale bars are 500 nm. Data were used for comparative analysis and presented as columns with bars representing means ± SD. Marks: *p≤0.05; **p≤0.01; ***p ≤ 0.001 and non-significant differences were indicated using ns symbol.

Journal: International Journal of Nanomedicine

Article Title: An Isolation System to Collect High Quality and Purity Extracellular Vesicles from Serum

doi: 10.2147/IJN.S328325

Figure Lengend Snippet: Comparison of two different combination methods and SEC. ( A ) Schematic overview of the experimental workflow. ( B ) total protein was determined by BCA (expressed as mg/mL originating serum; mean ± SD, n = 3). ( C ) the concentration of particles as detected by NTA (particles/mL originating serum; mean ± SD, n = 3). ( D ) the ratio of particle to protein for SEC, SEC+UC, and SEC+TEI. ( E ) size distribution of particles detected in C (representative for n = 3). The particle size at peak optimum is indicated. ( F ) samples were analyzed by SDS-PAGE followed by Bio-Safe Coomassie G-250. ( G ) the same samples were analyzed by Western blotting for the presence of the EV markers CD9, CD81, CD63, and the serum contaminant protein albumin and apolipoprotein marker apoA. The experiment shown is representative of 3 independent experiments. ( F and G ) SEC, SEC+UC, and SEC+TEI samples are all separated from equivalent volumes of 1mL originating serum, and the final volume is 100 μL. SEC+UCx3 samples were separated from 3mL originating serum, and the final volume is 100μL. All samples were loaded on equal volumes for electrophoresis. ( H ) The whole amount of TEM images of particles collected by SEC, SEC+UC, or SEC+TEI. Examples of EV-like structures (cup-shaped) are indicated by white arrows. Scale bars are 500 nm. Data were used for comparative analysis and presented as columns with bars representing means ± SD. Marks: *p≤0.05; **p≤0.01; ***p ≤ 0.001 and non-significant differences were indicated using ns symbol.

Article Snippet: CD9 was detected using rabbit anti-mouse CD9 (220642, Zen Bio, 1:1000); CD63 with rabbit anti-mouse CD63 (510953, Zen Bio, 1:1000); CD81 with rabbit anti-mouse CD81 (381296, Zen Bio, 1:1000); apoA1 with rabbit anti-mouse apoA1 (381145, Zen Bio, 1:1000); Albumin with rabbit anti-mouse Albumin (ab207327, Abcam, 1:1000).

Techniques: Comparison, Concentration Assay, SDS Page, Western Blot, Marker, Electrophoresis